Mineralocorticoid receptor antagonists: Part of an emerging treatment paradigm for chronic kidney disease

The Lancet Global Health

Volumn 2, Issue 12, 2014, Pages 925-927

  Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FINERENONE; SPIRONOLACTONE; ALDOSTERONE; MINERALOCORTICOID ANTAGONIST; PLACEBO; POTASSIUM; PROTECTIVE AGENT;

ALBUMINURIA; ARTERIAL STIFFNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY INJURY; MORTALITY; NONHUMAN; NOTE; OXIDATIVE STRESS; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANURIA; DRUG CONTRAINDICATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART INJURY; HEART PROTECTION; HYPERTENSION; OLIGOANURIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; ANALOGS AND DERIVATIVES; FEMALE; MALE;

ALBUMINURIA; FEMALE; HUMANS; HYPERTENSION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROTECTIVE AGENTS; SPIRONOLACTONE;

EID: 84933500874     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70216-5     Document Type: Note

References (10)

1. Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014, 383:1831-1843. for the Board of the EURECA-m Working Group of ERA-EDTA.
2. Shavit L, Lifschitz MD, Epstein M Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012, 81:955-968.
3. Brown NJ Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013, 9:459-469.
4. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN Effect of spironolactone on left ventricular mass and aortic stiffness in early stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009, 54:505-512.
5. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014, 63:528-536.
6. Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2014, for the EVALUATE Study Group, published online Oct 28. http://dx.doi.org/10.1016/S2213-8587(14)70194-9.
7. Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014, 64:69-78.
8. Kolkhof P, Borden SA Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012, 350:310-317.
9. Weir M, Bakris G, Mayo M, Stasiv Y, Christ-Schmidt H, Wittes J, Berman L A two-part trial of patiromer for the treatment of hyperkalemia in chronic kidney disease subjects on renin angiotensin aldosterone system inhibition. J Am Soc Nephrol 2013, 24:4B. (abstract SA-PO1085).
10. Singh B, Ash SR, Lavin P, Yang A, Rasmussen HS Effect of ZS-9, a novel selective cation trap, on urinary potassium and sodium excretion when used for the treatment of hyperkalemia in patients with chronic kidney disease. J Am Soc Hypertens 2014, 8(suppl):e15.